Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

FL118

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Canget

Drug class:

DDX5 degrader

‹

›

KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
TP53 mutation	Colorectal Cancer	TP53 mutation	Colorectal Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
APC mutation	Colorectal Cancer	APC mutation	Colorectal Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
DDX5 overexpression	Colorectal Cancer	DDX5 overexpression	Colorectal Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
TP53 mutation	Pancreatic Ductal Adenocarcinoma	TP53 mutation	Pancreatic Ductal Adenocarcinoma	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
DDX5 overexpression	Pancreatic Ductal Adenocarcinoma	DDX5 overexpression	Pancreatic Ductal Adenocarcinoma	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
HRAS mutation	Bladder Cancer	HRAS mutation	Bladder Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
KRAS mutation	Bladder Cancer	KRAS mutation	Bladder Cancer	FL118 Sensitive: D – Preclinical FL118 Sensitive : D	FL118 Sensitive: D – Preclinical FL118 Sensitive : D
ROR2 overexpression	Melanoma	ROR2 overexpression	Melanoma	FL118 Resistant: D – Preclinical FL118 Resistant : D	FL118 Resistant: D – Preclinical FL118 Resistant : D